Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16005330 | 0.93 | MAPT (0.45) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16005098 | 0.92 | MAPT (0.46) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16146375 | 0.92 | MAPT (0.44) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16005155 | 0.91 | MAPT (0.44) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16005315 | 0.90 | MAPT (0.42) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16145636 | 0.90 | MAPT (0.48) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16145733 | 0.88 | MAPT (0.41) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16005302 | 0.88 | EGFR (0.48) | MAPTMAPK1KMT2AELANEMEN1 | |
| SCHEMBL16005515 | 0.87 | MAPT (0.40) | MAPTMAPK1KMT2AELANESCN9A | |
| SCHEMBL16005545 | 0.86 | MAPT (0.46) | MAPTMAPK1KMT2AELANESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2774914-B1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | UNIV NANJING MEDICAL (CN) | 2017-12-06 | — | — | EP | claimed |
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | claimed |
| EP-2774914-B1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | UNIV NANJING MEDICAL (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-9481636-B2 | N-benzylaniline derivative and uses thereof | NANJING MEDICAL UNIVERSITY (CN) | 2016-11-01 | — | — | US | disclosed |
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2774914-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Nanjing Medical University (CN) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | NLN, INA, TRPV1 | MAPT 887/4885MAPK1 950/4885KMT2A 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.